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ABSTRACT
We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently
developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study.

INTRODUCTION
Gastrointestinal (GI) infection by cytomegalovirus (CMV) primarily afﬂicts patients who are immunosuppressed,
occurring in association with transplantation, malignancy, human immunodeﬁciency virus (HIV) infection, and
chronic steroid usage.1,2 T cell–mediated immunity is essential in restraining CMV replication and reactivation; thus,
abnormalities of lymphocyte number, function, or tissue distribution may impact patient susceptibility to infection.3
Treatment with natalizumab, which binds a 4-integrins, promotes such an immunocompromised state by blocking
adhesion interactions required for lymphocyte trafﬁcking, thus perturbing normal immunosurveillance. While
numerous studies have discussed natalizumab-associated infections of the central nervous system, fewer studies
have addressed infectious sequelae at other anatomic sites.

CASE REPORT
A 35-year-old woman presented in September 2015 with two weeks of nausea, vomiting, and epigastric pain, with
no fevers, chills, or GI bleeding. Her past medical history was notable for multiple sclerosis (MS) diagnosed in 2012,
no prior history of GI disease, and no history of recurrent or opportunistic infections that would suggest immunodeﬁciency. Her medications included ergocalciferol, dosed at 50,000 units per week since October 2013, and natalizumab, dosed at 300 mg every 4 weeks since February 2015; she denied use of alcohol and nonsteroidal antiinﬂammatory drugs. The patient’s only prior MS therapy was a 6-month trial of dimethyl fumarate started
December 2013, with no prior treatment with steroids.
On physical examination, the patient was in no apparent distress and exhibited normal vital signs. Abdominal exam
showed a non-tender, non-distended abdomen with normal bowel sounds and no palpable masses. Complete
blood count showed a white blood cell count of 4,900/mL (absolute neutrophil and lymphocyte counts were 1,700/
mL and 2,710/mL, respectively), hemoglobin 10.5 g/dL, and platelet count 168,000/mL. Basic chemistry, hepatic
function, lipase, and coagulation testing were normal. The patient was HIV-negative, and periodic John
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Figure 1. Upper GI endoscopy demonstrating severe inﬂammation of the
(A) body and (B) antrum of the stomach, with signiﬁcant erythema, erosions, and friability of the involved mucosa.

Cunningham (JC) virus serology testing since starting natalizumab was negative. Immunoglobulin and cortisol levels, as
well as counts of CD4þ and CD8þ T lymphocytes, were not
assessed. Barium upper GI ﬂuoroscopy demonstrated no
esophageal dilatation or stricture, hiatal hernia, reﬂux, or
ulceration of the esophagus or duodenum. Helical computed
tomography scans of abdomen and pelvis with intravenous
contrast were unremarkable.
Upper GI endoscopy revealed severe inﬂammation of the
entire examined stomach, with mucosal erosions and erythema and without ulceration or mass lesions (Figure 1). Cold
forceps biopsies of the gastric antral mucosa were obtained
for histopathologic analysis. Microscopic examination of hematoxylin and eosin-stained tissue showed a chronic inﬂammatory inﬁltrate and nuclear enlargement of the glandular
epithelial cells consistent with reactive changes (Figure 2).
Occasional epithelial cell nuclei showed prominent nucleoli
and possible intranuclear inclusions. Immunostaining for CMV
was positive, while it was negative for herpes simplex virus

Figure 3. Immunohistochemical staining for CMV shows strong nuclear
reactivity among the enlarged cells.

and Helicobacter pylori (Figure 3). Rapid urease testing of the
biopsy tissue was negative. On the basis of these ﬁndings, a
ﬁnal diagnosis of severe chronic active CMV gastritis was
rendered.
The patient completed a 3-week course of valganciclovir,
dosed at 900 mg twice per day. She reported complete resolution of her symptoms on follow-up with her infectious
disease physician 1 week after ﬁnishing treatment. Due to
her clinical improvement, the patient declined repeat endoscopy. Natalizumab was continued as her MS symptoms
were well-controlled; she has continued follow-up with her
neurologist approximately every 3 months and has denied
recurrence of her GI symptoms.

DISCUSSION
CMV has a broad cellular tropism and can cause disease in
nearly any organ; within the GI tract, the colon and stomach
are the most commonly affected sites.1,4 Deﬁnitive diagnosis
of CMV gastritis relies on endoscopy and biopsy. Grossly,
mucosal erosion and ulceration may be observed, with hemorrhage, obstruction, or perforation seen in more severe cases.
Unusual tissue morphologies of CMV gastritis, with polypoid
or pseudotumoral appearance on endoscopy, have been
described.5,6 Microscopically, infected cells may show cytomegaly and intracellular viral inclusions with a surrounding
clear zone ("owl’s eye" inclusions).2,7

Figure 2. Hematoxylin and eosin staining of gastric antrum tissue demonstrating severe chronic mucosal inﬂammation and occasional enlarged
cells with prominent intracellular inclusions (arrowheads).
ACG Case Reports Journal / Volume 4

CMV gastritis is a rare condition, with approximately 110 cases
described in the literature. Presenting symptoms are generally nonspeciﬁc, including nausea, vomiting, and epigastric
pain, although several unique presentations have been
described, including protein-losing gastropathy with generalized edema, postural epigastric pain, chronic dysmotility, and
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gastrocolic ﬁstula formation.8-11 The majority of reported
patients were immunocompromised, although several cases
in immunocompetent patients have been described.8,12 CMV
gastritis is typically self-limited and can be managed supportively in healthy patients, but antiviral treatment was frequently initiated in the reported cases if patients were
immunosuppressed or had severe or persistent disease.2
Complete recovery was often achieved with resolution of the
pathologic endoscopic ﬁndings, though notably adult cases
of protein-losing gastropathy showed poorer prognosis than
their pediatric counterparts.8
Natalizumab has primarily been associated with progressive
multifocal leukoencephalopathy secondary to JC virus reactivation.13 Consequently, clinical and laboratory assessment of
patient immune status, including total leukocyte and T-lymphocyte counts, history of opportunistic infection and prior
immunosuppressive therapy, and periodic JC virus serologic
screening have been recommended for patients taking this
medication.14,15 Other atypical infections, including herpes
simplex and varicella zoster virus encephalitis and meningitis,
as well as CMV colitis, have also been described.16,17 Notably,
CMV colitis has also been reported with the use of vedolizumab, an a4 b 7-integrin speciﬁc antibody used to treat inﬂammatory bowel disease.18
We hypothesize that CMV gastritis and colitis in patients taking natalizumab or vedolizumab share a common pathogenesis, whereby lymphocyte a4-integrin blockade disrupts
normal mucosal immunosurveillance. Consistently, the cell adhesion molecule MAdCAM-1, which binds a4 b 7-integrins, is
expressed by gut endothelial cells, particularly during inﬂammation.19 Human studies and mouse models of H. pylori gastritis have demonstrated dense lymphocytic inﬁltration of
MAdCAM-1–positive tissue foci, implicating this receptor in
recruiting circulating lymphocytes into the gastric mucosa.19,20
More studies, however, are necessary to solidify the connection between CMV gastritis and natalizumab; given the rarity
of this condition, accrual of greater numbers of natalizumabtreated patients will likely be necessary. Detailed immunologic workup will be particularly helpful in excluding other
causes of immunodeﬁciency. Finally, animal models of viral GI
infection in the setting of integrin blockade may provide important proof-of-principle and pathophysiologic insights to
how natalizumab impacts susceptibility to CMV GI infection.
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